NASDAQ:NERV Minerva Neurosciences (NERV) Stock Price, News & Analysis → Dave Ramsey Shocks Millions With US Dollar Lunacy (From American Hartford Gold Group) (Ad) Free NERV Stock Alerts $2.40 +0.06 (+2.56%) (As of 10:04 AM ET) Add Compare Share Share Today's Range$2.33▼$2.4050-Day Range$2.34▼$2.8352-Week Range$2.29▼$13.49Volume4,312 shsAverage Volume92,922 shsMarket Capitalization$16.78 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Minerva Neurosciences alerts: Email Address Minerva Neurosciences MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside199.1% Upside$7.00 Price TargetShort InterestHealthy0.56% of Float Sold ShortDividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews Sentiment0.61Based on 15 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.89) to ($3.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.92 out of 5 starsMedical Sector193rd out of 908 stocksPharmaceutical Preparations Industry80th out of 424 stocks 3.0 Analyst's Opinion Consensus RatingMinerva Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMinerva Neurosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.56% of the float of Minerva Neurosciences has been sold short.Short Interest Ratio / Days to CoverMinerva Neurosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Minerva Neurosciences has recently decreased by 24.32%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMinerva Neurosciences does not currently pay a dividend.Dividend GrowthMinerva Neurosciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMinerva Neurosciences has received a 71.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for Parkinsonism", "Clinical research services for schizophrenia", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Minerva Neurosciences is -0.89. Previous Next 3.1 News and Social Media Coverage News SentimentMinerva Neurosciences has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Minerva Neurosciences this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Minerva Neurosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Minerva Neurosciences is held by insiders.Percentage Held by InstitutionsOnly 34.56% of the stock of Minerva Neurosciences is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Minerva Neurosciences are expected to decrease in the coming year, from ($1.89) to ($3.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Minerva Neurosciences is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Minerva Neurosciences is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Birch GoldThe Sneaky IRS Tax Law that's Sweeping the U.S.In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.Request your info kit on gold now About Minerva Neurosciences Stock (NASDAQ:NERV)Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Read More NERV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NERV Stock News HeadlinesMay 6, 2024 | americanbankingnews.comMinerva Neurosciences (NASDAQ:NERV) PT Lowered to $7.00 at HC WainwrightMay 6, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Minerva Neurosciences, Inc. (NASDAQ:NERV) Reduced by HC WainwrightMay 7, 2024 | Birch Gold (Ad)The Sneaky IRS Tax Law that's Sweeping the U.S.In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.May 4, 2024 | americanbankingnews.comBrokers Issue Forecasts for Minerva Neurosciences, Inc.'s Q1 2025 Earnings (NASDAQ:NERV)May 1, 2024 | finanznachrichten.deMinerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business UpdatesMay 1, 2024 | chron.comMinerva Neurosciences: Q1 Earnings SnapshotMay 1, 2024 | markets.businessinsider.comMinerva Neurosciences Reports First Quarter 2024 Financial Results and Business UpdatesMay 1, 2024 | globenewswire.comMinerva Neurosciences Reports First Quarter 2024 Financial Results and Business UpdatesMay 7, 2024 | Birch Gold (Ad)The Sneaky IRS Tax Law that's Sweeping the U.S.In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.April 29, 2024 | msn.comUnique Far North steam experience closer after new boiler arrives for SS MinervaApril 27, 2024 | yahoo.comAlliance Elks announce teens of month for AprilApril 20, 2024 | msn.comPolice: 3 injured in Minerva Park single-vehicle crashApril 20, 2024 | msn.comOff-duty firefighters & neighbor rescue baby, residents from burning Minerva houseApril 4, 2024 | msn.comPrairie voles display signs of human-like depression, show promise as animal modelMarch 31, 2024 | msn.comNew track and field season gives Minerva sprinter Kyleigh Lippincott a fresh startMarch 14, 2024 | msn.comPotts Point homelessness encampment moved on from Minerva-Metro Theatre siteMarch 14, 2024 | tmcnet.comMinerva Named "One to Watch" in Chartis Financial Crime and Compliance 50 RankingsMarch 13, 2024 | msn.comRenovated Manti Temple, preserved Minerva Teichert murals ready for 3-week public open houseMarch 13, 2024 | tmcnet.comMinerva Named Top AI & Data Product in the 2024 Product AwardsFebruary 27, 2024 | markets.businessinsider.comHold Rating on Minerva Neurosciences Amid FDA Setbacks and Financial ConstraintsFebruary 27, 2024 | finance.yahoo.comMinerva schizophrenia drug rejected by FDAFebruary 27, 2024 | marketwatch.comFDA Turns Away Minerva's Roluperidone Schizophrenia DrugFebruary 27, 2024 | morningstar.comMinerva Neurosciences Shares Slide on Latest FDA Roluperidone SetbackFebruary 27, 2024 | msn.comRegulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More DataFebruary 27, 2024 | msn.comMinerva falls as FDA rejects schizophrenia therapyFebruary 27, 2024 | bizjournals.comFDA rejects Burlington biotech’s schizophrenia drug, sends stock tumblingFebruary 27, 2024 | reuters.comUS FDA declines to approve Minerva Neurosciences' schizophrenia drugSee More Headlines Receive NERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/06/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NERV CUSIPN/A CIK1598646 Webwww.minervaneurosciences.com Phone(617) 600-7373FaxN/AEmployees9Year Founded2007Price Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+199.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,000,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-53.19% Debt Debt-to-Equity RatioN/A Current Ratio12.58 Quick Ratio12.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.07) per share Price / Book-0.57Miscellaneous Outstanding Shares6,990,000Free Float6,545,000Market Cap$16.36 million OptionableNot Optionable Beta0.27 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Remy Luthringer Ph.D. (Age 63)Executive Chairman & CEO Comp: $853.58kMr. Geoffrey Robin Race F.C.M.A. (Age 63)M.B.A., President Comp: $628.46kMr. Frederick W. Ahlholm CPA (Age 58)Senior VP, CFO & Secretary Comp: $567.49kMr. Joseph Reilly (Age 49)Senior VP & COO Comp: $461kMr. William B. Boni (Age 72)Vice President of Investor Relations & Corporate Communications Prof. Michael Davidson M.D. (Age 74)Chief Medical Officer Comp: $657.47kMore ExecutivesKey CompetitorsVBI VaccinesNASDAQ:VBIVNeuroBo PharmaceuticalsNASDAQ:NRBOCocrystal PharmaNASDAQ:COCPFSD PharmaNASDAQ:HUGEAytu BioPharmaNASDAQ:AYTUView All Competitors NERV Stock Analysis - Frequently Asked Questions Should I buy or sell Minerva Neurosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NERV, but not buy additional shares or sell existing shares. View NERV analyst ratings or view top-rated stocks. What is Minerva Neurosciences' stock price target for 2024? 1 equities research analysts have issued 12 month price targets for Minerva Neurosciences' shares. Their NERV share price targets range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 199.1% from the stock's current price. View analysts price targets for NERV or view top-rated stocks among Wall Street analysts. How have NERV shares performed in 2024? Minerva Neurosciences' stock was trading at $6.15 at the beginning of the year. Since then, NERV stock has decreased by 62.0% and is now trading at $2.34. View the best growth stocks for 2024 here. Are investors shorting Minerva Neurosciences? Minerva Neurosciences saw a decline in short interest in April. As of April 15th, there was short interest totaling 30,500 shares, a decline of 24.3% from the March 31st total of 40,300 shares. Based on an average trading volume of 115,900 shares, the short-interest ratio is presently 0.3 days. Currently, 0.6% of the shares of the company are short sold. View Minerva Neurosciences' Short Interest. When is Minerva Neurosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our NERV earnings forecast. How were Minerva Neurosciences' earnings last quarter? Minerva Neurosciences, Inc. (NASDAQ:NERV) issued its quarterly earnings data on Wednesday, May, 1st. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, beating analysts' consensus estimates of ($1.20) by $0.07. When did Minerva Neurosciences' stock split? Shares of Minerva Neurosciences reverse split before market open on Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of Minerva Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD). How do I buy shares of Minerva Neurosciences? Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NERV) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyDollar CancelledLear CapitalUrgent Alert: Is the U.S. Implementing a Digital Dollar?Gold Gate CapitalDave Ramsey Shocks Millions With US Dollar LunacyAmerican Hartford Gold GroupTrump is sounding the alarmPreserve GoldBiden’s Sneaky H.R. 5376 Is A Nightmare For Retirement SaversBirch GoldIs Tesla going out of business?DTIAI “wealth window” is closing June 25thParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
